ReviewClinical and translational science2018
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Review in Clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.Breast cancer research : BCR · 2024Pooled it
- Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.Journal of pharmacokinetics and pharmacodynamics · 2026Trial
- Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.Clinical pharmacology and therapeutics · 2019Trial
- Beyond theJCO precision oncology · 2026Review
- Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFCancer chemotherapy and pharmacology · 2026Article
- Bayesian Ordered Lattice Design for Phase I Clinical Trials.Statistics in medicine · 2026Article
- A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point.BMC medical research methodology · 2025Article
- Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.Clinical and translational science · 2025Article
- An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.Cancer chemotherapy and pharmacology · 2025Article
- Moving the needle for oncology dose optimization: A call for action.CPT: pharmacometrics & systems pharmacology · 2024Article
- Moving the needle for oncology dose optimization: A call for action.Clinical and translational science · 2024Article
- Deep Learning Insights into the Dynamic Effects of Photodynamic Therapy on Cancer Cells.Pharmaceutics · 2024Article
- Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.Cancer chemotherapy and pharmacology · 2024Review
- Article
- Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.Clinical and translational science · 2024Article
- Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.Journal of patient-reported outcomes · 2023Article
- PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.CPT: pharmacometrics & systems pharmacology · 2023Article
- Interleukin-10 in cancer immunotherapy: from bench to bedside.Trends in cancer · 2023Review
- Clinical outcome assessment trends in clinical trials-Contrasting oncology and non-oncology trials.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.